CTRI/2011/05/001711暂停1 期
Randomized, Double blind, Placebo controlled Phase I Ib Study of P3914 to Evaluate the Safety, Tolerability, Food effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain
Piramal Life Sciences Limited0 个研究点目标入组 90 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •for Part A, Part B & Part C
- •1.Male subjects aged between 18 and 45 years (including both) with Body Mass Index between 18 to 25 kg/m2 (including both).
- •2.Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range.
- •3.Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
- •4.Subjects having clinically acceptable X-Ray chest (P/A view).
- •5.Subjects having clinically acceptable endoscopy.
- •6.Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
- •7.Have negative alcohol breath test.
- •8.Subjects willing to adhere to the protocol requirements and to provide written informed consent.
- •Patients with acute postoperative dental pain (at least moderate in severity or score of 40 mm on VAS) after removal of an impacted third mandibular molar will be selected for study participation, if they meet the following criteria:
- •1.Male patients aged between 18 and 60 years (including both).
- •2.Patients with acute postoperative dental pain (at least moderate in severity or score of 40 mm on Visual Analogue Scale)
- •3.Patients with otherwise normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range.
- •4.Patients having clinically acceptable 12-lead electrocardiogram (ECG).
- •5.Patients having clinically acceptable chest X-Ray (P/A view).
- •6.Patients having clinically acceptable endoscopy.
- •7.Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
- •8.Have negative alcohol breath test.
- •9.Patients willing to adhere to the protocol requirements and to provide written informed consent.
排除标准
- •for Part A, Part B & Part C
- •1.Hypersensitivity to NSAIDs or nitrodonating drugs.
- •2.History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
- •3.Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within one month of the study starting.
- •4.History or presence of significant gastric and/or duodenal ulceration including the last three months or gastroduodenal bleeding including the last six months prior to the screening visit.
- •5.History of peptic ulceration or significant dyspepsia as judged by the investigator.
- •6.Endoscopy finding of gastric or duodenal ulcer at baseline. Erosive esophagitis or other endoscopic appearance that constitutes a risk to the subject, if included in the study, as judged by the investigator.
- •7.Have positive test for Helicobacter pylori infection.
- •8.Orthostatic hypotension with a systolic blood pressure drop of ¡Ý 25 mm Hg and/or a diastolic blood pressure drop of ¡Ý 15 mm Hg within 5 minutes of standing when changing from supine to erect position.
- •9.A history of renal impairment, or a glomerular filtration rate (GFR) 60 mL/min or, at visit 1, a serum creatinine value 140 mol/L.
- •10.Use of aspirin, H2 antagonists, antacids, misoprostol, proton pump inhibitors, sucralfate including two weeks prior to the screening visit.
- •11.Subjects currently taking sildenafil, anticoagulants or ticlopidine, nitrates, nitrovasodilating drugs (e.g. nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, glycerin trinitrate), diuretics (in a dose potentially leading to volume depletion).
- •12.Use of any prescribed medication during last two weeks or OTC medicinal products (including herbal/traditional medicine preparations) during the last one week prior to initiation of study.
- •13.History or presence of significant alcoholism or drug abuse in the past one year.
- •14.Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- •15.History or presence of smoking or use of other tobacco, pan, gutkha products since last six months.
- •16.History or presence of significant asthma, urticaria or other allergic reactions.
- •17.History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour.
- •18.Difficulty in swallowing solids like tablets or capsules.
- •19.History or presence of cancer.
- •20.Difficulty with donating blood.
- •21.Major illness during three months before screening.
- •22.Participation in a drug research study within past three months.
- •23.Donation of blood in the past three months before screening.
- •1.Hypersensitivity to NSAIDs or nitrodonating drugs.
- •2.History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
- •3.Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
- •4.History or presence of significant gastric and/or duodenal ulceration including the last three months or gastroduodenal bleeding including the last six months prior to the screening visit.
- •5.History of pept
研究者
相似试验
进行中（未招募）
1 期
A Study of Ibrutinib in Combination with Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 20.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 100000004864EUCTR2012-000600-15-PTJanssen-Cilag International NV580
进行中（未招募）
1 期
A Study of Ibrutinib in Combination with Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.EUCTR2012-000600-15-GBJanssen-Cilag International NV578
进行中（未招募）
1 期
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASHigh- or very-high risk, localized or locally advanced prostate cancerCTIS2023-505246-26-00Janssen - Cilag International1,315
进行中（未招募）
1 期
A Study of Ibrutinib in Combination with Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 14.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000600-15-GRJanssen-Cilag International NV578
进行中（未招募）
1 期
A Study of Ibrutinib in Combination with Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 14.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000600-15-ESJanssen-Cilag International NV580